Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

OBJECTIVE To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. METHODS This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. RESULTS At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). CONCLUSION Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.

[1]  Mahboob Rahman,et al.  Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation , 2013, Annals of the rheumatic diseases.

[2]  C. Naugler,et al.  Fasting time and lipid levels in a community-based population: a cross-sectional study. , 2012, Archives of internal medicine.

[3]  O. Baser,et al.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy , 2012, Arthritis care & research.

[4]  Jeffrey R Curtis,et al.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. , 2012, Arthritis and rheumatism.

[5]  J. Daurès,et al.  Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis , 2012, Annals of the rheumatic diseases.

[6]  Ricardo Blanco,et al.  Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. , 2011, Arthritis and rheumatism.

[7]  I. Holme,et al.  Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. , 2011, Rheumatology.

[8]  T. Therneau,et al.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease , 2011, Annals of the rheumatic diseases.

[9]  M. Turiel,et al.  The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. , 2010, Autoimmunity reviews.

[10]  T. Pincus,et al.  Lipoprotein Subclasses Determined by Nuclear Magnetic Resonance Spectroscopy and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[11]  M. Nurmohamed,et al.  Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study , 2010, Annals of the rheumatic diseases.

[12]  M. Hochberg,et al.  Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity , 2010, Annals of the rheumatic diseases.

[13]  M. Suarez‐Almazor,et al.  A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis , 2010, Clinical Rheumatology.

[14]  M. Rizzo,et al.  Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. , 2009, Atherosclerosis.

[15]  T. Therneau,et al.  Total cholesterol and LDL levels decrease before rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[16]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[17]  F. Wolfe,et al.  The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. , 2008, Arthritis and rheumatism.

[18]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[19]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[20]  S. Gabriel,et al.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? , 2007, Annals of the rheumatic diseases.

[21]  E. Pérez-Pampín,et al.  All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists , 2007, Annals of the rheumatic diseases.

[22]  C. Stefanadis,et al.  Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. , 2007, International journal of cardiology.

[23]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[24]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[25]  J. Avorn,et al.  Patterns of cardiovascular risk in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[26]  M. Cutolo,et al.  Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .

[27]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[28]  D. O'leary,et al.  Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. , 2005, Arthritis and rheumatism.

[29]  S. van der Linden,et al.  Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[30]  L. Eberly,et al.  Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. , 2003, Archives of internal medicine.

[31]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[32]  R. Moots,et al.  Corticosteroids: do they damage the cardiovascular system? , 1994, Postgraduate medical journal.

[33]  B. Myones,et al.  Dyslipoproteinemia in the course of active rheumatoid arthritis. , 1992, Seminars in arthritis and rheumatism.

[34]  P. Wilson,et al.  Efficacy of lipid profiles in prediction of coronary disease. , 1992, American heart journal.

[35]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[36]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[37]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[38]  K. Feingold,et al.  Beneficial effects of cytokine induced hyperlipidemia. , 1998, Zeitschrift für Ernährungswissenschaft.